Most US neurologists prescribing MS drugs have received pharma industry cash
Higher volume prescribers more likely to receive payments; and recipients more likely to prescribe that company’s drugs, especially if payments were larger, sustained, and recent Nearly 80% of US neurologists prescribing drugs for multiple sclerosis (MS) received at least one pharma industry payment, with higher volume prescribers more likely to ...